The cardiovascular benefit of GLP-1 receptor agonists is not explained by weight loss.
- Current status
- ProbableEvidence stable · Cardiovascular
- Why
- In SELECT (obesity + CVD, no diabetes) MACE reduction was consistent across baseline weight categories and showed no linear relationship with early weight loss; an estimated 33% of benefit was mediated via waist reduction. This is the one linked analysis that relates MACE to weight change: SELECT's primary report, its hsCRP analysis, the type 2 diabetes CVOT meta-analysis and SURPASS-CVOT show benefit but do not test whether it is explained by weight loss. This supports mechanisms beyond adiposity in people who already have obesity and atherosclerotic disease; it does not show benefit in people without excess adiposity.
- What would change it
- A primary-prevention outcome trial in people without obesity (would strengthen).
A weight-matched comparison showing loss of CV benefit when weight loss is equalised (would weaken). - Linked studies
- 6 · 1 supports · 4 consistent, but doesn't test the claim · 1 doesn't directly test the claim
- Last updated
- Oct 19, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
The evidence, sorted by what it shows
Supports (1)
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
Prespecified SELECT analysis: benefit independent of baseline adiposity and early weight loss; ~33% mediated by waist circumference change.
Consistent, but doesn't test the claim (4)
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisPrespecified secondary (sub-study) analysis of a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (select) · 2026 · Study tier 2 · Different population · Benefit · Industry funded
Prespecified SELECT analysis (ASCVD with overweight or obesity, no diabetes): semaglutide lowered hsCRP, including before major weight loss and in people without weight loss, but greater hsCRP reductions went with greater weight loss; modelling attributes part of the MACE benefit to inflammation, but hsCRP is a biomarker and the pathway is not separated from weight loss.
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
SURPASS-CVOT in type 2 diabetes with ASCVD: tirzepatide was noninferior to dulaglutide for MACE (HR 0.92, 95.3% CI 0.83 to 1.01) but not superior (P = 0.09). A larger weight-losing agent showed no significant extra benefit, but the arms also differ in GIP action and glycaemic effect, so this is not a weight-matched test.
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
SELECT primary result in adults with established CVD and BMI 27 or greater without diabetes: semaglutide reduced MACE (hazard ratio, 0.80; 95% CI, 0.72 to 0.90). The primary report shows benefit exists but does not test whether it is explained by weight loss.
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
Meta-analysis of eight cardiovascular outcome trials (60,080 patients with type 2 diabetes): GLP-1 receptor agonists reduced MACE (HR 0.86, 95% CI 0.80-0.93), with no significant heterogeneity across subgroups including baseline BMI. Weight change was not analysed, so it does not test whether benefit is explained by weight loss.
Doesn't directly test the claim (1)
- Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
Umbrella review of meta-analyses in people with overweight or obesity: GLP-1 RA reductions in MACE and MI were significant with high-certainty evidence overall but no longer significant in patients without baseline CVD. It did not analyse weight loss.
How this assessment has changed
- ProbableOct 19, 2026 · Evidence stable
Owner decision 2026-10-18 on IN-061 (claims audit): recommended options accepted (IN-061.23). Status unchanged; rationale corrected to match the audited links; trend strengthening -> stable.
- ProbableSep 13, 2026 · Evidence strengthening
initial curated status